Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers

OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteolol and latanoprost in OPC-1085EL ophthalmic solution by formulating the combination drug will be determined.

Inclusion Criteria:

• Subjects who are considered medically healthy per investigator's judgment

Exclusion Criteria:

• Subjects with ocular conditions as defined by the protocol
• Subjects with intraocular pressure: <10 or ≥22 mmHg